Michael Pearson's "Leap Day" return to Valeant Pharmaceuticals International Inc. was supposed to be a victory for the CEO and his firm after he'd spent the past few months on sick leave recovering from a severe bout of pneumonia.
But before Pearson could get his footing, Valeant got shoved off a cliff on Feb. 29 – tumbling 21% after...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
